CTXR earnings analysis
What we found in CTXR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The latest quarter showed $2.0 million of revenue, down 50.0% sequentially from $4.0 million, while diluted EPS deteriorated to -$0.95 from -$0.38. Gross margin was resilient at 80.3%, but operating margin was deeply negative at -1,931.0%. The filing adds material financing risks at Citius Oncology, including a 12.75% interest-rate floor, a $1,062,500 maturity payment, and milestone-dependent access to Tranches 2 and 3.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Gross margin remains above 80%
- Gross margin remained strong at 80.3% in the latest quarter, broadly stable versus 80.0% in the prior quarter and 80.3% in the comparable available period.
- LYMPHIR remains the revenue focus
- The company reported $2.0 million of revenue in the latest quarter, with LYMPHIR identified in the filing data as the principal product revenue category.
- Controls assessed as effective
- Disclosure controls and procedures were concluded effective as of June 30, 2026, and management reported no material changes to internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High-cost debt and balloon payment
- Citius Oncology’s loan carries a floating interest rate with a 12.75% annual floor, includes interest-only payments before amortization, and requires a $1,062,500 final payment at maturity, increasing refinancing and liquidity risk.
- Milestone-dependent funding
- Access to Tranche 2 and Tranche 3 is conditional on specified net revenue and liquidity milestones; failure to meet those milestones would eliminate access to additional committed capital under the loan agreement.
- Potential equity dilution
- Lenders may convert up to $4.0 million of principal at $1.08 per share and hold warrants equal to 10% of funded loans exercisable at $0.90 per share, creating potential dilution and market-price pressure.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.95
- Gross margin
- 80.3%
- Operating margin
- -1931.0%
- Segment
- LYMPHIR: revenue contribution is not separately quantified in the provided filing text
What they said about what is next.
The provided 10-Q extract contains no quantitative revenue or EPS outlook. Prior commentary referenced ongoing LYMPHIR-driven revenue growth, but this filing excerpt does not provide updated numeric guidance.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Citius Pharmaceutical's Q2 2026 10-Q reveals a notable increase in product revenue with the commercial launch of LYMPHIR, generating $1.67 million in revenue for the quarter. However, the company reported a substantial…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CTXR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever